Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Schwind

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Haematologica|October 15, 2020
High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- populationMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Hemasphere|November 15, 2019
Prognostic Impact of Blood <i>MN1</i> Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid LeukemiaMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Oncotarget|December 22, 2017
ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemiaCarolina Yaeko Namasu, Christiane Katzerke, Daniela Bräuer-Hartmann, et al.
Bone Marrow Transplantation|December 4, 2018
Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantationJuliane Grimm, Marius Bill, Madlen Jentzsch, et al.
Leukemia|October 25, 2023
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantationLara Bischof, Jule Ussmann, Juliane Grimm, et al.
British Journal of Haematology|February 26, 2013
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adultsChristine L Phillips, Stella M Davies, Richard McMasters, et al.
Hemasphere|March 19, 2024
Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?Sebastian Schwind, Lara Bischof, Marius Bill, et al.
Frontiers in Oncology|October 4, 2021
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two CasesKristin Gerhardt, Madlen Jentzsch, Thomas Georgi, et al.
Annals of Hematology|May 23, 2018
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patientsMarius Bill, Juliane Grimm, Madlen Jentzsch, et al.
Bone Marrow Transplantation|December 2, 2025
The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantationGeorg-Nikolaus Franke, Jule Ussmann, Donata Backhaus, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Haematologica|October 15, 2020
High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- populationMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Hemasphere|November 15, 2019
Prognostic Impact of Blood <i>MN1</i> Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid LeukemiaMadlen Jentzsch, Marius Bill, Juliane Grimm, et al.
Oncotarget|December 22, 2017
ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemiaCarolina Yaeko Namasu, Christiane Katzerke, Daniela Bräuer-Hartmann, et al.
Bone Marrow Transplantation|December 4, 2018
Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantationJuliane Grimm, Marius Bill, Madlen Jentzsch, et al.
Leukemia|October 25, 2023
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantationLara Bischof, Jule Ussmann, Juliane Grimm, et al.
British Journal of Haematology|February 26, 2013
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adultsChristine L Phillips, Stella M Davies, Richard McMasters, et al.
Hemasphere|March 19, 2024
Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?Sebastian Schwind, Lara Bischof, Marius Bill, et al.
Frontiers in Oncology|October 4, 2021
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two CasesKristin Gerhardt, Madlen Jentzsch, Thomas Georgi, et al.
Annals of Hematology|May 23, 2018
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patientsMarius Bill, Juliane Grimm, Madlen Jentzsch, et al.
Bone Marrow Transplantation|December 2, 2025
The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantationGeorg-Nikolaus Franke, Jule Ussmann, Donata Backhaus, et al.
Pageof 11